Pre-therapeutic Analysis of the Individual Radiosensitivity of Cancer Patients in Luxembourg (APRI-Lux): Prospective National Interventional Study With Minimal Risk
Not Applicable
- Conditions
- CancerRadiosensitivityRadiation Toxicity
- Registration Number
- NCT05433974
- Lead Sponsor
- Centre Francois Baclesse, Luxembourg
- Brief Summary
Pre-therapeutic analysis of the individual radiosensitivity of cancer patients in Luxembourg
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Patient over 18 years old
- Patient with an indication for curative radiotherapy
- Patient having given his signed written informed consent before any specific procedure of the protocol.
Exclusion Criteria
- Patient with a contraindication to radiotherapy
- Patient with an indication for palliative radiotherapy
- Patient with a history of radiotherapy in the area where the cancer is located
- Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Validation of RadioDtect test on early radiation-induced toxicity 3 months prospectively validate the predictive capacities of the RadioDtect individual radiosensitivity blood test on early radiation-induced toxicity. The validation will be based on ATM protein assay and rate of acute toxicities of grade ≥ 2 to 3 months according to NCI-CTCAE v4.03 criteria
- Secondary Outcome Measures
Name Time Method Validation of RadioDtect test on delayed radiation-induced toxicity 12 months to prospectively validate the predictive capacities of the RadioDtect individual. radiosensitivity blood test on delayed radiation-induced toxicity at 12 months. The validation will be based on ATM protein assay and rate of acute toxicities of grade ≥ 2 to 3 months according to NCI-CTCAE v4.03 criteria